Filing Flows › Companies › Corcept Therapeutics › Timeline
Corcept Therapeutics stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−0.4% to $72.77
Corcept Therapeutics (CORT) stock fell 0% over the last 252 sessions, to $72.77. On the way it reported 4 quarters, its insiders filed 5 open-market trades and 12 Form 144 notices of planned sales, and the company filed 2 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 3, 2026 | Earnings | Earnings: beat the EPS estimate by 20.2% | +1.8% (+1.5% vs SPY) | — | — |
| Oct 1, 2026 | Form 144 | Form 144: Joseph Douglas Lyon plans to sell $1.2M | −1.0% (−1.2% vs SPY) | +3.7% (+1.8% vs SPY) | −29.3% (−30.2% vs SPY) |
| Sep 23, 2026 | 8-K | Directors and officers: departures, appointments, pay | −4.0% (−3.2% vs SPY) | −2.4% (−1.2% vs SPY) | −1.0% (−1.0% vs SPY) |
| Sep 15, 2026 | Form 144 | Form 144: James Wilson plans to sell $3.3M | −0.9% (−0.4% vs SPY) | +1.7% (−0.2% vs SPY) | +5.2% (+2.7% vs SPY) |
| Sep 14, 2026 | Form 144 | Form 144: Joseph Douglas Lyon plans to sell $1.1M | −0.9% (−0.4% vs SPY) | −2.2% (−2.1% vs SPY) | +7.2% (+5.1% vs SPY) |
| Sep 2, 2026 | Form 144 | Form 144: Roberto Wandenkolk Vieira plans to sell $8.3M | −2.6% (−3.1% vs SPY) | +2.0% (+1.9% vs SPY) | +0.6% (0.0% vs SPY) |
| Aug 26, 2026 | Form 144 | Form 144: Kimberly Park plans to sell $3.3M | −3.1% (−3.1% vs SPY) | −8.6% (−8.1% vs SPY) | −4.2% (−4.6% vs SPY) |
| Aug 26, 2026 | Insider sale | Park Kimberly sold $3.3M | −3.1% (−3.1% vs SPY) | −8.6% (−8.1% vs SPY) | −4.2% (−4.6% vs SPY) |
| Aug 25, 2026 | Form 144 | Form 144: Sean Maduck plans to sell $22.0M | +0.3% (−0.1% vs SPY) | −8.4% (−8.8% vs SPY) | −8.7% (−9.5% vs SPY) |
| Aug 18, 2026 | Form 144 | Form 144: David L Mahoney plans to sell $12.2M | +0.8% (+1.5% vs SPY) | +5.1% (+6.2% vs SPY) | −4.7% (−2.2% vs SPY) |
| Aug 17, 2026 | Form 144 | Form 144: Gary Charles Robb plans to sell $1.2M | +2.3% (+2.8% vs SPY) | +6.6% (+7.9% vs SPY) | −3.2% (−0.8% vs SPY) |
| Aug 17, 2026 | Insider sale | Robb Gary Charles sold $1.2M | +2.3% (+2.8% vs SPY) | +6.6% (+7.9% vs SPY) | −3.2% (−0.8% vs SPY) |
| Aug 4, 2026 | Form 144 | Form 144: William Guyer plans to sell $2.3M | −2.7% (−4.5% vs SPY) | +1.3% (−0.8% vs SPY) | +0.5% (0.0% vs SPY) |
| Aug 3, 2026 | Form 144 | Form 144: Joseph Douglas Lyon plans to sell $176K | −1.5% (−2.9% vs SPY) | −3.3% (−6.8% vs SPY) | −1.0% (−3.6% vs SPY) |
| Aug 3, 2026 | Insider sale | Lyon Joseph Douglas sold $176K | −1.5% (−2.9% vs SPY) | −3.3% (−6.8% vs SPY) | −1.0% (−3.6% vs SPY) |
| Jul 30, 2026 | Form 144 | Form 144: Atabak Mokari plans to sell $4.6M | +24.1% (+22.5% vs SPY) | +17.5% (+12.1% vs SPY) | +23.0% (+17.4% vs SPY) |
| Jul 29, 2026 | Earnings | Earnings: beat the EPS estimate by 535.3% | −1.3% (+0.2% vs SPY) | +15.3% (+11.3% vs SPY) | +24.0% (+20.7% vs SPY) |
| Jul 7, 2026 | Form 144 | Form 144: William Guyer plans to sell $1.9M | +2.6% (+3.1% vs SPY) | −6.4% (−6.2% vs SPY) | +18.1% (+15.5% vs SPY) |
| Jun 17, 2026 | Insider sale | Mahoney David L sold $1.7M | −2.4% (−1.1% vs SPY) | −2.6% (−0.5% vs SPY) | +7.8% (+8.5% vs SPY) |
| May 28, 2026 | 8-K | Directors and officers: departures, appointments, pay | +1.6% (+1.4% vs SPY) | +9.1% (+8.8% vs SPY) | +25.1% (+26.7% vs SPY) |
| May 27, 2026 | Insider sale | Lyon Joseph Douglas sold $325K | +9.9% (+9.9% vs SPY) | +16.5% (+15.3% vs SPY) | +33.9% (+35.9% vs SPY) |
| Apr 30, 2026 | Earnings | Earnings: missed the EPS estimate by -111.3% | −0.2% (−1.1% vs SPY) | +11.3% (+8.2% vs SPY) | +39.9% (+33.8% vs SPY) |
| Feb 24, 2026 | Earnings | Earnings: missed the EPS estimate by -39.4% | +3.2% (+2.4% vs SPY) | +1.8% (+1.2% vs SPY) | −4.4% (−0.3% vs SPY) |
Insiders’ record here
In the year on the chart, Corcept Therapeutics' insiders reported 0 open-market buys ($0) and 5 sales ($6.6M). Of the 3 old enough to score, 1 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale +37.6%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Corcept Therapeutics: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.